Chief executive officer, uniQure
Appears in 1 story
Leading the company through regulatory review
uniQure filed its Huntington's disease gene therapy, called AMT-130, for approval in the United States and the United Kingdom on September 2, 2026. If approved, it would be the first disease-modifying treatment for a disease that today has none.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
